Company Filing History:
Years Active: 2011
Title: Jochen Huber: Innovator in Pharmaceutical Research
Introduction
Jochen Huber is a notable inventor based in Frankfurt-am-Main, Germany. He has made significant contributions to the field of pharmaceutical research, particularly in the development of compounds that target critical health issues.
Latest Patents
Jochen Huber holds a patent for "Pyrazolopyridine derivatives as inhibitors of β-Adrenergic receptor kinase 1." This invention relates to 6-amido substituted pyrazolopyridine derivatives that are useful as inhibitors of beta-adrenergic receptor kinase 1 (βARK-1). The compounds are designed for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia, and hepatitis C virus (HCV) infections. Additionally, they are aimed at preventing opiate addiction. He has 1 patent to his name.
Career Highlights
Jochen Huber is associated with Sanofi-Aventis, a leading global biopharmaceutical company. His work at Sanofi-Aventis has allowed him to focus on innovative solutions in the pharmaceutical industry.
Collaborations
Throughout his career, Jochen has collaborated with esteemed colleagues such as Henning Steinhagen and Kurt Ritter. These partnerships have contributed to the advancement of his research and the successful development of his inventions.
Conclusion
Jochen Huber's contributions to pharmaceutical research exemplify the impact of innovation in addressing significant health challenges. His work continues to influence the field and offers hope for improved treatments in the future.